Circulating tumor DNA as an early marker of therapeutic response in ...

Circulating tumor DNA as a biomarker for monitoring early treatment ...

We found that changes in ctDNA levels were strongly associated with tumor response. A > 30% decrease in ctDNA at t1 correlated with a longer PFS ...

Recent Advancements in the Application of Circulating Tumor DNA ...

Clinicians can use ctDNA analysis to track disease development, predict therapy response, and detect minor residual illness or relapse earlier ...

Monitoring and adapting cancer treatment using circulating tumor ...

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications in cancer management. While its role in guiding ...

Clinical utility of circulating tumor DNA as a response and follow-up ...

Through recent technological innovations, new methods for measuring tumor burden and treatment response are becoming available. By utilization ...

Early circulating tumor DNA dynamics at the commencement of ...

Early circulating tumor DNA dynamics following radiotherapy has not been well studied. · ctDNA levels were associated with treatment responses.

Circulating Tumor DNA Predicts Early Treatment Response in ...

SAN DIEGO — Monitoring a patient's circulating tumor DNA (ctDNA) can provide valuable insights on early response to targeted therapies among ...

Circulating tumor DNA: a promising biomarker in the liquid biopsy of ...

Moreover, ctDNA analysis is capable of accurately determining the tumor progression, prognosis and assisting in targeted therapy. Therefore, ...

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer

For evaluating therapy response, ctDNA appears to be especially useful in patients receiving targeted therapies against driver oncogenes or ...

Circulating Tumor DNA as a Biomarker for Monitoring Patients with ...

These biomarkers however, lack specificity for cancer and have poor sensitivity in detecting early recurrences and monitoring therapy ...

circulating tumor DNA (ctDNA) - Know Your Biomarker

ctDNA can be measured in blood to identify the presence of residual cancer cells after surgery or to monitor for cancer recurrence after successful treatment.

Early ctDNA kinetics as a dynamic biomarker of cancer treatment ...

Circulating tumor DNA assays are promising tools for the prediction of cancer treatment response. Here, we build a framework for the design ...

The Use of Circulating Tumor DNA to Monitor and Predict Response ...

An important premise for utilizing ctDNA as a tool for assessment of response to treatment is that it must be a reliable marker of tumor burden, where changes ...

Assessing the Use of ctDNA as an Early Endpoint in Early-Stage ...

At what time point does ctDNA response (e.g., early response from pre-treatment to ... Circulating tumor DNA in neoadjuvant-treated breast cancer reflects ...

The Use of Circulating Tumor DNA to Monitor and Predict Response ...

CTDNA shows enormous promise as a sensitive biomarker for monitoring response to many treatment modalities and for targeting therapy as well as enabling ...

The interplay of circulating tumor DNA and chromatin modification ...

ctDNA detection of cancer patients allows the early assessment of the drug response, especially the identification of therapeutic resistance ...

Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis

ctDNA has great potential as a blood-based biomarker for the detection and treatment of cancer in its early stages.

Circulating tumor DNA to guide diagnosis and treatment of localized ...

As a result of the improvement in the techniques for DNA analysis, above all next-generation sequencing (NGS) assays, circulating tumor DNA (ctDNA) has become ...

Circulating tumor DNA mutation analysis: advances in its application ...

Overall, despite the existing challenges, the examination and analysis of ctDNA have opened up new avenues for early diagnosis and therapeutic efficacy ...

Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for ...

Emerging data have shown that circulating tumor DNA (ctDNA) can be used as a potential molecular biomarker to predict residual disease in solid ...

Circulating tumor DNA detectable in early- and late-stage colorectal ...

Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene mutations in tumors, in addition to monitoring ...